Accession Number:

AD1100002

Title:

A New Paradigm for the Treatment of Ovarian Cancer: The Use of Epigenetic Therapy to Sensitize Patients to Immunotherapy and Chemotherapy

Descriptive Note:

Technical Report,30 Sep 2018,29 Sep 2019

Corporate Author:

Johns Hopkins University Baltimore United States

Personal Author(s):

Report Date:

2019-10-01

Pagination or Media Count:

72.0

Abstract:

Our overall goal remains to bring epigenetic therapy to have major impact for the management of advanced ovarian cancer OC. This past year, we continue to make exciting advances in our pre-clinical work and interim results from our leveraged clinical trial is pending now for low dose therapy targeting DNA demethylation paired with immune checkpoint therapy. The results of our two relevant, published studies of mouse models have attracted a great deal of attention, including our study of a OC model in which we have identified that the demethylating agent, 5-aza-cytidine AZA potently stimulates tumor immune attraction of T-cells to the tumor microenvironment PNAS, 2017. For components of this treatment paradigm, Cell, 2017, PNAS, 2017, during the past year we have broadened the degree of immune pathway signaling involved for OC as described in our report below. Studies of how an inhibitor of G9A, an enzyme mediating transcriptional repression, might can augment the above AZA effects for OC continue as well Cancer Res, 2018. All of the above findings continue to document how epigenetic therapy can potentially improve immune checkpoint therapy for OC.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE